Apramar – biologically active dietary supplement, based on the organic isolated Amygdalin nitriloside. The Ministry of Health, Labour and Social Protection of Moldova included Apramar in the list of supplements officially approved by the government (see Directive №990 released on 13.12.2017) .

Todicamp S.R.L. - a family company named after Michael Petrovich Todica, the inventor of “Todicamp” extract. The original dietary supplement is made under the trademark ТОДИКАМП® only.

Amygdalin (the natural variant of Laetrile). Ernst Theodore Krebs, an American biochemist, promoted laetrile in 1952 . He classified the element as a vitamin of B group with №17. Despite everything, amygdalin was never assigned with a patent. It was applied during oncological diseases treatment in clinics of the USA, Germany, Mexico, Russia, the Philippines, and other countries till 1973 .

The exploring of laetrile by Dr. Kanematsu Sugiura  caused a scandal. The research was made on the basis of laboratories of large pharmaceutical corporation Sloan-Kettering . After that, amygdalin-based medications were forbidden by FDA. As of today, the investigation is still going on.

Ralph Moss, the former Sloan-Kettering employee, dismissed after accusing laboratory management of a lie, and some other Dr. Sigiura supporters say that the greater part of researches acknowledging amygdalin as being ineffective, were fabricated. Another accusation that laetrile might be dangerous because of cyanide glycoside high toxicity does not have any proven facts: there are no cases of death caused by cyanide poisoning during laetrile treatment recorded so far.

Apramar (laetrile, B17, amygdalin) is supposed to fill the cells with glycosides to enhance the immunity and generally nourish the organism. The implementation of this cure is to balance the deficit of amygdalin, which contents rapidly decreased in the modern individual diet because of mass consumption of GMO and fast food. There are no isolated B17 in nature (the name of the vitamin is conventional due to no official patent has been obtained yet). But it is possible to find amygdalin in some berries, fruits, legume crops.

According to the first results of Dr. Kanematsu Sugiura's research  laetrile administration (isolated B17 concentrate) along with other biocatalysts reduces the potency of tumors and therefore favors better status of patients with malignant disease.

• Professor Itor Guidetti from Turin Medical School University on B17 clinical trial: “In some cases, everyone could observe a group of tumor masses rapidly dissolving”

• Shigeaki Sakai, Japan: “Prescribed to the people ill with cancer, laetrile proved that it causes no collateral damage. I should say that there is no anti-cancer solution which improves the situation for the oncological patient faster than laetrile”

• Dr. Robin. B. Navarro, the Philippines: “This is my carefully checked clinical conclusion, both as the researcher and the oncologist with practice, that I achieved the most important and encouraging results only using Laetrile-Amygdalin in the treatment of clinical cancer patients, and that these results are incommensurable and immeasurably higher than the results I achieved using more toxic standard cytotoxic drugs”

http://lex.justice.md/viewdoc.php?action=view&view=doc&id=373925&lang=2

http://www.canceruncensored.com/dr-krebs-and-vitamin-b17/

http://reinisch.blog.cz/1602/2-metabolicheskoe-lechenie-onkozabolevanij

http://cancerres.aacrjournals.org/content/40/7/2625

http://science.sciencemag.org/content/198/4323/1231

https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.2930100202